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Abstract  
Many Leishmania (Viannia) parasites harbor the double-stranded RNA virus Leishmania RNA virus 1 
(LRV1), which has been associated with increased disease severity in animal models and humans, and 
drug treatment failures in humans. Remarkably, LRV1 survives in the presence of an active RNAi 
pathway, which in many organisms controls RNA viruses. We found significant levels (0.4-2.5%) of small 
RNAs derived from LRV1 in both L. braziliensis and L. guyanensis, mapping across both strands and with 
properties consistent with Dicer-mediated cleavage of the dsRNA genome. LRV1 lacks cis or trans-acting 
RNAi inhibitory activities, suggesting that virus retention must be maintained by a balance between 
RNAi activity and LRV1 replication. To tilt this towards elimination, we targeted LRV1 using long-
hairpin/stem-loop constructs similar to those effective against chromosomal genes. LRV1 was 
completely eliminated, at high efficiency, accompanied by a massive overproduction of LRV1-specific 
siRNAs, representing as much as 87% of the total. For both L. braziliensis and L. guyanensis, RNAi-
derived LRV1-negative lines were no longer able to induce a Toll-like receptor 3-dependent hyper-
inflammatory cytokine response in infected macrophages. This is the first demonstration of a role for 
LRV1 in L. braziliensis virulence in vitro, the Leishmania species responsible for the vast majority of 
mucocutaneous leishmaniasis cases. These findings establish the first targeted method for elimination of 
LRV1, and potentially of other Leishmania viruses, which will facilitate mechanistic dissection of the role 
of LRV1-mediated virulence. Moreover, our data establish a third paradigm for RNAi-viral relationships 
in evolution, one of balance rather than elimination. 
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Significance statement:  
Leishmania parasites can be infected with Leishmaniavirus (LRV1), a double-stranded RNA virus whose 
presence in L. guyanensis parasites exacerbates disease severity in both mouse models and humans. 
Studies of the role of the virus on parasite biology and virulence are hampered by the dearth of isogenic 
lines bearing and lacking LRV, particularly in the clinically important species L. braziliensis. Here we 
describe a method to systematically generate LRV1-free Leishmania parasites using the parasite RNA 
interference (RNAi) pathway. The ability of transgene-driven RNAi to overcome the ability of LRV1 to 
withstand the endogenous RNAi attack suggests a new paradigm of virus-RNAi interaction, where RNAi 
and virus replication exist in balance to maintain persistent infection. 
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Introduction 
Leishmania is a genus of early-diverging protozoan parasites that cause leishmaniasis in many 
regions of the world, with an estimated 12 million symptomatic cases, at least 120 million asymptomatic 
cases, and nearly 1.7 billion at risk (1-5). The disease has three predominant clinical manifestations, 
ranging from the relatively mild cutaneous form to mucocutaneous disease, where parasites 
metastasize to and cause destruction of mucous membranes of the nose, mouth, and throat, and fatal 
visceral disease. Disease phenotypes segregate primarily with the infecting species; however, it is not 
fully understood which parasite factors affect severity and disease manifestations. 
One recently identified parasite factor contributing to disease severity in L. guyanensis is the 
RNA virus Leishmaniavirus (6, 7). This virus is a member of the Totiviridae family, and consists of a single-
segmented dsRNA genome that encodes only a capsid protein and an RNA-dependent RNA polymerase 
(RDRP) (8, 9). It is most frequently found (as LRV1) in New World parasite species in the subgenus 
Viannia such as L. braziliensis (Lbr) and L. guyanensis (Lgy), which cause both cutaneous and 
mucocutaneous disease (6), but it has also been found sporadically in Old World subgenus Leishmania 
species (as LRV2) (10, 11). Like most totiviruses, LRV1 is neither shed nor infectious, and thus can be 
viewed as a long-term evolutionary endosymbiont whose activities on the mammalian host arise 
indirectly through the parasite, rather than by direct infection of the mammalian host by the virus (6). 
Previous work has shown that mice infected with LRV1-bearing strains of Lgy exhibit greater footpad 
swelling and higher parasitemia than mice infected with LRV1-negative Lgy (7). Similarly, macrophages 
infected in vitro with LRV1+ Lgy or LRV2+ L.aethiopica release higher levels of cytokines, phenotypes 
which were dependent on Toll-like receptor 3 (7, 10). The assignment of the LRV1-specificity of these 
phenotypes benefited greatly from the availability of a single isogenic LRV1-free line of Lgy (12). 
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Importantly, recent studies show that disease severity is increased in patients infected with LRV1+ Lgy, 
relative to LRV1-negative parasites (13).  
In humans, Lbr is associated with cutaneous leishmaniasis, as well as the larger share of the 
more debilitating mucocutaneous leishmaniasis (MCL) (14, 15). While in some studies LRV1 was not 
correlated with MCL (16, 17), in others there was a strong association (6, 18, 19). Recent studies show 
that LRV1 in Lbr and Lgy clinical isolates correlates with drug treatment failure (16, 20). Thus, while 
other parasite or host factors may play a significant role in the development of MCL (21, 22), current 
data support a role for LRV1 in exacerbating the pathogenesis of human leishmaniasis caused by Lbr and 
Lgy.  A similar role in pathogenicity has been proposed for the Trichomonas vaginalis totiviruses (23).   In 
contrast, endobiont viruses in other systems more often impair the host or have no known effect on 
disease.  Hypoviruses of Cryphonectria parasitica are associated with decreased virulence of their fungal 
host, while the L-A totivirus of Saccharomyces cerevisiae is not thought to affect  pathogenicity, instead 
contributing to inter-microbial competition (24-27) . 
Research into the role of LRV1 in Lbr disease is hampered by the fact that animal models are less 
well developed than for other Leishmania (28), and the absence of isogenic lines bearing or lacking 
LRV1. Since reverse genetic systems for Totiviridae do not exist and attempts to stably transfer LRV1 
have proven unsuccessful (29), we asked whether RNA-interference (RNAi) could be used to generate 
LRV1-free isogenic isolates. Unlike Old World Leishmania, species of the Viannia subgenus, including Lbr 
and Lgy, retain an active endogenous RNAi pathway (30). The RNAi pathway converts double-stranded 
RNA into siRNAs, which trigger the degradation of an mRNA with complementary sequence (31). 
Importantly, the RNAi pathway acts as a defense against RNA viruses in plants and some animals, 
leading to great reductions or complete elimination (32, 33). Further, introduction of RNAi pathway 
proteins from Saccharomyces castellii into the naturally RNAi-null S. cerevisiae resulted in greatly 
decreased levels of persistently-infecting L-A totivirus (26). In mammals, siRNA-mediated RNAi activity 
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appears to play a smaller direct role in antiviral responses in adult mice (34, 35), although evidence of a 
direct response has been found in embryonic stem cells and young animals (36, 37). 
Here we explore further the interactions of the RNAi pathway with LRV1 in both Lbr and Lgy, 
and show first that LRV1 is indeed seen by the endogenous RNAi pathway, as judged by the presence of 
significant levels of antiviral sRNAs. Thus and different than other systems, RNAi and viral replication 
appear to be balanced. However, by increased siRNA expression RNAi could be used to efficiently 
eliminate the virus. Importantly, these LRV1 negative transfectants recapitulate the in vitro macrophage 
cytokine release defect seen in naturally-occurring LRV1-negative lines, suggesting that the engineered 
LRV1-negative isogenic lines will be valuable in studying the role of LRV1-mediated biology and 
virulence. 
Results 
Naturally abundant siRNAs directed against LRV1 of L. braziliensis and L. guyanensis 
Previous siRNA studies in Leishmania analyzed RNAs using a tagged Argonaute inserted into an 
ago1- knockout of Lbr M2903, which lacks LRV1 (9, 29, 38, 39). Because the lines bearing LRV1 studied 
here had not been similarly modified, we sequenced total small RNAs (sRNAs) as an alternative. Lbr 
siRNAs bear a 5’-P and 3’-OH, reflecting their origin through the action of cellular Dicer nucleases (39), 
and we used these properties to make siRNA-focused sRNA (<42 nt) libraries for next-generation 
sequencing (Table S1). For Lgy we chose the established LRV1+ Lgy M4147 strain (7), and three different 
Lbr shown to bear LRV1 by PCR and/or anti-dsRNA antibody tests (40).  
For sRNAs from Lbr M2903 mapping to the Lbr reference genome, read length displayed a 
biphasic distribution, with a major peak centered around 23 nt (20-26 nt, 77.9% of total mapped reads) 
and a minor one around 33 nt (30-36nt, 9.4% of total mapped reads) (Fig. 1A, Table S1,S2). The 33 nt 
peak reads mapped primarily to structural RNA loci (62% of mapped reads; Table S2) similar to a sRNA 
class described in many eukaryotes including trypanosomes and Leishmania lacking the RNAi pathway 
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(41-44). In contrast, reads from the 23 nt peak showed properties similar to AGO1-bound siRNAs (39), 
including their size and the presence of 1-2 untemplated nucleotides at the 3’ end in about 21% of the 
reads (Fig. 1A; Table S1). The 3’ untemplated bases likely arise from the action of cellular terminal 
transferases, as Leishmania sp. lack the HEN1 methyltransferase that normally blocks their action (39). 
When both AGO1-bound siRNAs and the 23 nt sRNA peak reads were mapped to the Lbr genome their 
distributions were very similar, with the vast majority mapping to transposable elements (Figs. 1B, S2; 
Table S2) (39). We concluded that the 23 nt peak sRNAs (23 nt sRNAs) provides a reasonable proxy for 
siRNAs.  
The properties of sRNAs from the LRV1-bearing Lgy M4147 and Lbr LEM2700, LEM2780 and 
LEM3874 mapping to the Lgy or Lbr reference genomes were similar to those of Lbr M2903, including 
the 23 and 33 nt sRNA peaks, genomic mappings, and the presence and level of 3’ nt extensions in the 
23nt sRNAs (Figs. 1, S1; Tables S1 & S2). Importantly, a substantial fraction of sRNA reads obtained from 
the LRV1+ Lgy and Lbr lines mapped to the LRV1 genomes, ranging from 0.4-2.5% of the 23nt mapped 
reads (Fig. 1B, Table S1). Unlike those aligned to the nuclear genome, LRV1-mapped reads showed a 
single size distribution centered around 23 nt (Fig. 1A), with about 20% again showing short 3’ 
extensions (Table S1), typical of Lbr siRNAs and 23 nt sRNAs (39). LRV1-mapping 23 nt sRNAs showed no 
consistent strand- or region-specific biases in all four strains (Fig. S2), suggesting that they likely 
originated from the action of DICERs on the viral dsRNA genome. 
We previously showed that LRV1 does not encode a trans-acting inhibitor of RNAi activity (30), 
and the presence of high levels of LRV1-directed sRNAs similarly suggests that it does not encode a 
strong cis-acting inhibitor. Importantly, the levels of 23 nt sRNAs mapping to LRV1s were in the same 
range as siRNAs mapping to an efficiently silenced Luciferase reporter (0.4–2.5% vs. 0.8% targeted by 
long hairpin/stem loop transgene) (30, 39). Thus, LRV1 is able to persist in the face of a significant RNAi 
response, as judged by 23 nt sRNA levels.  
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LRV1 can be efficiently targeted by transgenic RNAi 
These data are consistent with a model where RNAi activity and LRV1 replication has achieved a 
‘balance’ between viral synthesis and degradation, which might be shifted by increasing or decreasing 
RNAi activity. With an eye towards virus elimination, we focused on increasing LRV1-targeting siRNA 
levels through the use of transgenic RNAi methods developed previously (30), in which long hairpin RNA 
is expressed at high levels from a stem-loop (StL) construct containing LRV1 sequences integrated into 
the ribosomal RNA locus (Fig. 2A). We targeted regions of LRV1 from the capsid or RDRP ORFs (Lgy 
M4147, Lbr LEM2700 and LEM2780), or a region that spanned them (Lbr LEM3874), ranging in length 
from 794 to 1,143 bp (Fig. 2B & Table S3); since the two viral genes reside within the same RNA 
segment, targeting either should lead to degradation of the entire LRV1 RNA. Since LRV1 sequences 
diverge substantially between parasite strains (69-90% nt identity), ‘stems’ specific for each 
species/strain were used. To assess non-specific effects, we integrated an StL construct for an AT-rich 
GFP (GFP65 StL), which efficiently silences expression of GFP65 (30). The untransfected parental lines 
served as LRV1+ controls, and Lbr M2903 or Lgy M4147/HYG (12) served as LRV1-negative controls.  
To screen for loss of LRV1, StL transfectants were analyzed by flow cytometry of fixed, 
permeabilized cells using an antibody raised against the Lgy M4147 LRV1 capsid (45), which cross reacts 
with Lbr LRV1. For both Lgy M4147 (Fig. 3, top) and Lbr LEM2780 (Fig. 3, bottom), there was a clear 
separation in capsid staining between the LRV1-positive (red) and LRV1-negative controls (green). While 
control GFP65 StL lines (purple) had capsid protein levels similar to WT, capsid protein was undetectable 
in LRV1-targeted StL lines (Fig. 3, light & dark blue), indistinguishable from the LRV1-negative control. 
This was observed whether the capsid or RDRP was targeted (Fig. 3). Similar results were obtained with 
LRV1 StL transfectants from Lbr LEM2700 and Lbr LEM3874. In support of the flow cytometry data, 
western blot analysis with an anti-capsid antibody showed high LRV1 levels in the Lgy parental line and 
GFP65 StL transfectants, while capsid protein was undetectable in the capsid StL transfectants (Fig. S3).  
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StL constructs result in high levels of siRNAs mapping to the LRV1 stem 
 Despite the insensitivity of LRV1 to ‘natural’ levels of RNAi, as judged by the abundance of 23nt 
sRNAs, introduction of StL constructs targeting LRV1 resulted in great reduction in LRV1 levels. To 
understand the basis for this, we analyzed 23 nt sRNA peak reads mapping to the nuclear and LRV1 
genomes, for one LRV1 StL transfectant of each species (Fig. 4). Remarkably, the percentage of total 23 
nt sRNAs mapping to LRV1 had increased greatly from that seen in the WT parent, from 2.5% to 86.7% 
for Lgy and from 1.8% to 73.0% for Lbr LEM3874 (Figs. 4A, S4). Concomitantly, the percentages of 23 nt 
sRNAs mapping to the nuclear genome was proportionately reduced, with some variability amongst loci 
and/or lines (for example, rRNA reads were unchanged in both species, while tRNA reads decreased in 
Lgy; Figs. 4A, S1A). While we did not measure the absolute levels of sRNAs, previous studies show these 
are tightly controlled by the level of Argonaute 1 and thus are unlikely to differ significantly (39). 
Essentially all LRV1-mapping sRNAs in LRV1 StL lines now mapped only to the RNAi-targeted ‘stem’ 
region (Fig. 4B, dark grey), as expected since LRV1 had been eliminated (below). This also argues against 
the occurrence of ‘transitive’ siRNA formation (46, 47). 
 The levels of LRV1 23 nt sRNAs (76-87%) in LRV1 StL-transfectants were much greater than seen 
with siRNAs mapping to the LUC ORF/stem targeted using the same StL transfection construct (0.8%) 
(39). To rule out the possibility that this arose from reliance on 23nt sRNAs, we analyzed these from a 
line bearing the LUC StL RNAi reporter used in the siRNA studies (IR2-LUCStL(b)-LUC(a)). For this, 1.14% 
of the 23nt sRNA peak reads mapped to the LUC ORF/stem, suggesting that use of 23nt sRNAs vs siRNAs 
did not significantly impact quantitation. To assess the target-specific effects, we compared these results 
with those quantitating 23 nt peak sRNAs after RNAi StL targeting of a panel of 10 chromosomal genes. 
For this group, 1.5-34% of 23 nt sRNAs mapped to the RNAi-targeted gene, compared to less than 0.02% 
basally. Thus, the StL-bearing IR vectors generate a high but variable level of sRNAs for all genes tested, 
with the LUC reporter being at the low end and LRV1 at the high end. This may reflect the fact that while 
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the LRV1 target is typically eliminated by RNAi (Fig. 3 and below), chromosomal RNAi targets 
continuously transcribe mRNAs. In other organisms, studies have shown that the presence of a cognate 
target facilitates the turnover of sRNAs; thus, the absence of LRV1 target may lead to higher levels of 
siRNAs (48, 49). Future studies may address the factors contributing to the differences in sRNA levels 
amongst genes and to the very high steady-state levels of LRV1-directed 23 nt sRNAs seen here. 
Complete virus elimination following RNAi of LRV1 
RNAi-mediated LRV1 knockdown would be most useful as a tool if it resulted in a complete 
elimination of LRV1. To achieve a sensitivity beyond that of flow cytometry (~20 fold) or western 
blotting (~100 fold), we validated a sensitive quantitative RT-PCR assay (qRT-PCR) for LRV1, using strain- 
and LRV1-specific primers to amplify a region located outside the ‘stem’ regions (Table S4; Fig. 2B). Since 
the melting temperatures of PCR amplicons are sequence- and length-dependent, comparison of 
dissociation (melt) curves facilitated discrimination between specific and non-specific amplification. 
Because LRV1 copy number was estimated to be ~100/cell (50), a cutoff for classification as 
LRV1-negative was set at 104-fold below WT. Analysis of Lbr qPCR data by the ΔΔCt method (51) showed 
that most LRV1 StL transfectants had LRV1 RNA levels more than 105-fold lower than WT (Figs. 5A, 
S5A,B). Raw Ct values for LRV1 StL lines with LRV1-specific primers were indistinguishable from mock 
cDNA preparations, and ΔCt values were indistinguishable from those of negative controls. Melt curves 
show that products seen at Ct arose from non-specific amplification (Figs. 5A, S5A,B; white bars). As 
expected for control GFP65 StL lines, LRV1 RNA levels were similar to those in WT (Figs. 5A, S5A,B; black 
bars).  
Similar results were obtained with RNAi of LRV1 in Lgy M4147, with most transfectants showing 
reductions below the 104-fold cutoff (Fig. 5B). However, low levels of LRV1 remained in two lines where 
the RDRP was targeted, approximately 300- to 500-fold less than the parent line (Fig. 5B, black bars); 
here melt curve analysis suggested these products were LRV1-specific. Alternate primers targeting other 
12 
 
regions across the virus gave similar results, suggesting the presence of intact LRV1. We hypothesized 
that this was due to heterogeneity in viral load, with most but not all cells lacking LRV1. In support of 
this, we generated and showed that all clonal lines arising from one of the “weakly positive” lines were 
negative for LRV1 by flow cytometry and satisfied the 104-fold cutoff by qPCR (Fig. S5C). The occasionally 
incomplete LRV1 elimination is consistent with our prior observation that RNAi was somewhat less 
efficient in Lgy than in Lbr (30). Nonetheless, even for “weakly positive” Lgy transfectants, RNAi was 
sufficiently efficient for the ready isolation of LRV1-negative lines (Fig. 3, top; 5B; S3).  
LRV1 knockdowns induce less cytokine production in in vitro macrophage infection assays 
Previous reports showed that LRV1+ Lgy stimulated the TLR3-dependent release of higher levels 
of cytokines from bone marrow-derived macrophages (BMDMs) than LRV1-negative strains (7). The 
availability of defined RNAi-derived LRV1-negative lines now allowed tests of this in Lbr for the first time 
as well as confirmation of prior results obtained with a single isogenic LRV1- Lgy. Briefly, BMDMs were 
infected in vitro with LRV1 StL and GFP65 StL Lbr and Lgy transfectants, as well as positive and negative 
control lines, and the levels of two cytokines known to be induced by LRV1 (TNF-α and IL-6) (7, 10) were 
measured. 
Capsid StL and RDRP StL LRV1-negative lines of both Lbr and Lgy induced significantly lower 
levels of cytokine production than did the LRV1-positive lines (both parental and GFP65 STL) (Fig. 6, Fig. 
S5). Additionally, when macrophages from TLR3-deficient mice were infected with Lbr LEM2700, the 
LRV1-positive parasites no longer elicited higher levels of cytokine release (Fig. S5). Of note, all Lgy LRV1 
StL lines induced background levels of cytokine release, including the two lines that retained low levels 
of LRV1 (Fig. 5B & 6B, Fig. S5), consistent with the observation that high levels of LRV1 were necessary 
for cytokine stimulation (7, 10). 
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Discussion 
In this study we have characterized the endogenous RNAi response in Leishmania bearing the 
dsRNA virus LRV1, and used these insights to generate virus-negative lines that facilitate the study of the 
role of LRV1 in parasite biology and host-parasite interactions.  
Leishmania LRV1 and the endogenous RNAi pathway  
We identified two populations of sRNA in Lbr and Lgy. The less abundant 33 nt sRNAs mapped 
primarily to genes encoding structural RNAs (Table S2), as seen in other organisms including 
trypanosomatids (41-44). In contrast, the more abundant 23 nt sRNA fraction exhibited properties 
similar to authentic, AGO1-bound Lbr siRNAs (39), including size, the presence of 3’ untemplated bases 
at the same frequency (~20%), and mapping primarily to transposable elements and repetitive 
sequences (Fig 1; Tables S1 & S2). Only 23 nt sRNA reads mapped to the LRV1 dsRNA genome (Fig. 1A), 
and these also bore 3’ nucleotide extensions at the same frequency, again consistent with an origin via 
the RNAi pathway (Table S1). Importantly, the levels of 23 nt sRNAs mapping to LRV1 constituted a 
substantial fraction of total aligned 23nt sRNAs (Fig 1B, Table S1), comparable to those targeting an 
efficiently-silenced LUC reporter gene (30, 39). Thus, LRV1 can persist in the face of RNAi pressure that 
gives rise to sRNA levels comparable to that which efficiently silences a chromosomal target gene. 
In other organisms, sRNA/siRNA levels provide a gauge of RNAi pathway recognition and 
targeting of viruses: when RNAi controls virus replication, as in plants, fungi, and insects (26, 32, 33), 
high levels of siRNAs accompany viral infections, leading to eradication of the virus.  In mammals, 
quantitatively fewer siRNAs are present, which do not effectively control virus levels, at least in adult 
somatic tissues (34, 36, 37). In contrast, high levels of siRNA-like 23 nt sRNAs in Leishmania suggest an 
attack on LRV1 by the RNAi pathway, but the virus persists. While many viruses encode trans-acting 
RNAi suppressors mediating their survival (52), this seems unlikely for LRV1. There is no obvious coding 
potential for this in the compact LRV1 genome, our studies here suggest there is no strong cis-acting 
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inhibitory activity, and we showed previously that a luciferase reporter was equally silenced in the 
LRV1+ and LRV1-negative Lgy studied here (30). This suggests a third model where LRV1 is targeted 
strongly by the RNAi pathway, but the RNAi-mediated degradation is ‘balanced’ by virus replication or 
other factors. We are currently working to identify which component(s) of the RNAi machinery mediate 
this balance. While the slicer activity of Argonaute is perhaps the most likely agent, previous studies 
examining the role of RNAi in control of viruses frequently raise the possibility of Dicer-mediated control 
as well (53-55).  It is likely that the sequestration of the LRV1 dsRNA genome within the capsid may also 
contribute by limiting the exposure of the LRV1 dsRNA to the RNAi machinery and other degradative 
pathways.  In yeast, SKI genes act to prevent deleterious effects of L-A viruses towards its fungal host 
through alterations in mRNA degradation and/or surveillance (27), and homologous genes for several of 
these are evident in the Leishmania genome. 
In other organisms, persistent viruses can also be maintained in the face of an active RNAi 
pathway, but at considerably reduced levels (26, 56). Over evolutionary time, this strong pressure likely 
accounts for the inverse relationship in fungi between virus levels and the activity and/or presence of 
the RNAi pathway, especially when associated with a selective advantage for viral retention, as seen 
with the yeast killer factors which are dependent on the L-A virus (26, 57). Similarly, in Leishmania we 
had originally proposed that RNAi pressure would be sufficiently strong as to in some cases provide a 
driving force for loss of RNAi, in order to maintain LRV1-dependent increases in pathogenicity (30). 
Given the greater ability of LRV1 to survive in the presence of an active RNAi pathway, our data suggest 
that the magnitude of this effect may be considerably less than envisioned. However, even small 
pressure could prove a significant force towards down-regulating pathways impacting on LRV1 levels 
during evolution. 
RNAi as a tool for generating LRV1-negative lines for biology 
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Following the predictions of the ‘balance’ hypothesis, we aimed to increase activity against LRV1 
through the increased synthesis of siRNAs targeting LRV1. This proved quite successful; the fraction of 
23 nt sRNAs targeting LRV1 rose dramatically in lines expressing StL constructs targeting LRV1 (Figs. 1B & 
4A). Correspondingly, the fraction of 23 nt sRNAs mapping to the Leishmania genome dropped 
proportionately, most of which again mapped to TEs and repeats (Fig. 4A). Importantly, LRV1 levels were 
dramatically reduced for all LRV1 StL transfectants, and in most cases the virus eliminated, as judged by 
protein and RNA methods (Figs. 3, 5, S3, S5). Targeting of either the capsid or RDRP gene eliminated 
LRV1, as was expected given that both are encoded by the same RNA (Fig. 2A). Only in Lgy were some 
transfectants found that retained low levels of LRV1, which could reflect less RNAi activity in this 
species, as was seen with reporter genes (30). However, most transfectants had completely lost LRV1.  
Viral infection has been reported for Giardiavirus (58), and stable viral transfer for several fungal 
Totiviruses (59). However, de novo infection and stable viral transfer have been unsuccessful with Lgy 
(29), and reverse genetic systems have yet to be reported for any Totivirus. Therefore, the ability to 
reproducibly mediate viral cure by RNAi is of great value for biological studies of LRV1. Previous work 
used an LRV1-negative Lgy which was obtained following transfection with an episomal Leishmania 
vector expressing resistance to hygromycin B, followed by a long period of growth under selection (12); 
however, this method seems to have been successful only once. Neither have we succeeded with 
several ‘stress-related’ treatments that have proven effective in curing mycoviruses, such as yeast L-A 
(60). Our studies establish RNAi as a viable strategy for cure of LRV1 and perhaps other viruses in RNAi-
competent Leishmania species.  
LRV1+ but not LRV1-negative Lgy induce a ‘hyperinflammatory’ cytokine response in infections 
of BMDMs in vitro, which is TLR3-dependent (6, 7). Infectivity tests of mouse BMDMs in vitro showed 
that RNAi-generated LRV1-negative Lgy lines likewise failed to induce a substantial cytokine response, as 
shown for two cytokines (TNF-α and IL-6) known to be diagnostic for an LRV1-driven innate immune 
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response. Interestingly, this occurred with RNAi-derived lines where LRV1 loss was substantial but 
incomplete (RDRP StL c3 & 4; 500- and 300-fold below parental levels, respectively; Fig 5B, 6B, S7), 
consistent with data from natural Lgy showing low LRV1 levels (7). Thus, a partial reduction in LRV1 
levels is sufficient to ameliorate LRV1-dependent virulence, which may facilitate future efforts targeting 
LRV1 in human disease. Importantly, the continued presence of the integrated StL constructs appeared 
to have no ‘off target’ effect in the BMDM infections, despite the high levels of transgene-derived 23 nt 
sRNAs present in these lines; the LRV1 StL “cured” lines induced the release of cytokines at a level 
similar to that of StL-negative, LRV1-negative controls (Fig. 4), and control GFP65 StL lines that 
maintained LRV1 induced the release of cytokines at a level similar to the StL-negative, LRV1+ parent 
(Fig. 3, 5, 6). Future studies will assess whether this also pertains to other cell types or host infections. 
LRV1-dependent virulence in Leishmania braziliensis 
Previous studies of LRV1-dependent virulence focused primarily on Lgy; however, in humans, 
Lbr is associated with the larger share of MCL (14, 15). Our studies extend the generality of LRV1-
dependent virulence to Lbr, as LRV1+ Lbr likewise induce strong TLR3-dependent cytokine responses. 
These findings are especially important in light of published work on the association of LRV1 with MCL, 
with mixed results depending on the geographic region and methods used (6, 16-19). Our data show 
that in in vitro infections, LRV1 contributes strongly to the pro-inflammatory phenotype associated with 
elevated pathogenicity, as seen in Lgy. This suggests that in human infections it may be informative to 
seek for correlations between LRV1 and the severity of CL in Lbr infections in future studies. Indeed, 
recent studies show that LRV1 in Lbr clinical isolates correlates with drug treatment failure (16), as was 
also seen in Lgy (20). Thus, while other parasite or host factors may play a significant role in the 
development of MCL (21, 22), current data now bolstered by our studies of isogenic LRV1+/negative 
lines support a role for LRV1 in severity of human leishmaniasis caused by Lbr.  
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Methods 
Parasites and in vitro culture 
Lbr LEM2700 (MHOM/BO/90/AN), LEM2780 (MHOM/BO/90/CS) and LEM3874 (MHOM/BO/99/IMT252 
n°3) were from Patrick Bastien (Université de Montpellier), Lbr M2903 (MHOM/BR/75/M2903) was from 
Diane McMahon Pratt (Yale School of Public Health), and Lgy M4147 (MHOM/BR/78/M4147) and its 
derivative Lgy M4147/HYG was from Jean Patterson (Southwest Foundation for Biomedical Research, 
San Antonio, Texas). Prior to introduction of StL constructs, parasites were transfected with the linear 
SSU-targeting SwaI fragment from B6367 pIR2SAT-LUC(B) (30), and clonal lines were derived, validated, 
and used. The luciferase-expressing clone of Lbr LEM2780 contained only LRV1-LbrLEM2780(b). 
Parasites were grown in fresh Schneider’s Insect Medium supplemented with 10% heat-inactivated fetal 
bovine serum, 100 μM adenine, 10 μg/mL hemin, 2 μg/mL biopterin, 2 mM L-glutamine, 500 units/ml 
penicillin and 50 ug/mL streptomycin, and selective drugs as indicated below. 
RNAi Stem-loop Constructs 
Regions of interest from LRV1 were screened using the RNAit target selection tool to ensure that there 
was no homologous sequence in the parasite genome (61), amplified from cDNA by PCR using KlenTaq-
LA polymerase, and cloned into the pCR8/GW/TOPO cloning vector (Thermo Fisher Scientific, Waltham, 
Massachusetts) using the protocol recommended by the manufacturer and a 20 min ligation. The ‘stem’ 
segments and PCR primer sequences can be found in Table S3. The ‘stems’ were transferred from the 
pCR8/GW/TOPO donor vector to the pIR2HYG-GW(A) (B6365) destination vector (which contains 
sequence from the parasite rRNA locus to enable integration into the genome and inverted LR 
recombinase sites for the generation of inverted repeat through Gateway© technology) using LR 
Clonase II (Thermo Fisher) in an overnight reaction at room temperature. Reactions were terminated by 
incubating with proteinase K for 1 hour at 37°C. Constructs were verified by restriction digest. 
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Transfections 
Stable transfections were performed as previously described (30, 62). Clonal lines were obtained by 
plating on semisolid media with 50 µg/mL hygromycin B. After colonies formed, cells were grown to 
stationary phase in 1 mL media and passaged thereafter in 10 mL media with 30 µg/mL hygromycin B.  
RNA preparation and quantitative real-time PCR (qPCR) 
Total RNA was prepared from log-phase cells dissolved in Trizol reagent (Thermo Fisher) at 3 x 108 
cells/mL using the Direct-zol kit (Zymo Research, Irvine, California) and eluted in 50 µL of nuclease-free 
water. The RNA was DNAseI-treated (Thermo Fisher) in a 200 µL reaction using the provided buffer and 
20 Units of enzyme for 1 hour at 37 °C, purified using the RNA Clean & Concentrator - 25 kit (Zymo 
Research), and eluted in 50 µL of nuclease-free water. Reverse transcription was performed using the 
Superscript III first-strand synthesis kit (Thermo Fisher) according to the manufacturer instructions in a 
20 µL reaction containing 0.25 ug purified RNA. Control reactions contained the same amount of RNA 
but lacked reverse transcriptase enzyme. For qRT-PCR, primers were designed to amplify ~100 bp 
regions of the LRV1 genome that lie outside the stem regions (Table S4). qPCR reactions were performed 
with cDNA templates in 20 µL total reaction volume using the Power SYBR Green Master Mix (Thermo 
Fisher), 5 µL of ten-fold diluted cDNA, and final primer concentrations of 0.2 µM. Reactions were run on 
the ABI PRISM 7000 Sequence Detection System (Applied Biosystems, Thermo Fisher). PCR amplification 
conditions were as follows: 50 °C for 2 min and 95 °C for 10 sec followed by 40 cycles of 95 °C for 15 sec 
and 60 °C for 1 min. PCR products were confirmed to be specific by melt curve analysis. All experiments 
were performed in triplicate. Amplification of KMP-11 was used as an internal control to normalize 
parallel reactions. 
Small RNA (sRNA) sequencing 
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sRNA libraries were generated from total RNA as described (39); briefly, a primer (5'-
rApppATCTCGTATGCCGTCTTCTGCTTG/ddC for all samples except Lgy M4147, which used primer 
rApppTGGAATTCTCGGGTGCCAAGG/ddC) was ligated first to the 3’ end using truncated mutant T4 RNA 
Ligase (New England Biolabs), and then a second riboprimer (5'-GUUCAGAGUUCUACAGUCCGACGAUC) 
to the 5’ end with T4 RNA Ligase. cDNA was generated using reverse transcriptase and primer 5'-
CAAGCAGAAGACGGCATACGA, and then PCR was performed with this in conjunction with primer 5'-
AATGATACGGCGACCACCGACAGGTTCAGAGTTCTACAGTCCGA. Products corresponding to inserts of 10-
50 nt were purified, and taken for sequencing with Illumina HiSeq2500 technology. Sequences have 
been deposited in the NCBI Short Read Archive (accession SRP082553). 
Bioinformatic analysis of sRNAs 
The 5′ and 3′ adapter sequences were removed from the sRNA reads, those less than 15 nt 
removed, and the trimmed reads were mapped to homologous LRV1 or Leishmania genomes (Lbr 
M2904 (63) or a draft Lgy M4147 genome (Bioproject PRJEB82; accession CALQ01000001 – 
CALQ01004013)) using Novoalign software http://www.novocraft.com; parameters were set as  
-F ILMFQ; -H; -g 40; -x 6; -R 5; -r; and -e 1000). A random strategy was employed to align reads mapping 
to multiple regions and hard clipping of low coverage bases at 3’ end was performed. sRNA abundance 
was assessed directly, or after ‘collapsing’ to remove duplicate reads using algorithms within the fastx 
toolkit (http://hannonlab.cshl.edu/fastx_toolkit/index.html ). To annotate transposable or repeated 
elements, we used RepeatMasker ( http://www.repeatmasker.org) to identify known elements and/or 
BLAST to identify regions corresponding to Leishmania specific elements (SLACS, TAS, and TATE (63)) . 
The annotations were collected in .bed file format for further use. Coverage was calculated by counting 
the number of reads that align to each strand of the LRV1 genome. 
LRV1 sequences  
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From the sRNA sequences we assembled whole or partial LRV1 contigs, which were confirmed and 
completed by PCR amplification and sequencing. The sequences for LRV1-LbrLEM2700, LRV1-
LbrLEM2780(a) and (b), LRV1-LbrLEM3874, and a revision of the LRV1-LgyM4147 (formerly LRV1-4; (64)) 
genome sequences were deposited in GenBank (accession numbers KX808483-KX808487). 
LRV1 capsid flow cytometry.  
 The development and optimization of this protocol will be described elsewhere (F.M. Kuhlmann et al. in 
preparation). Briefly, 1 x 107 cells were fixed at room temperature (RT) using 2% paraformaldehyde 
(Thermo Fisher) in PBS for 2 min, and then then incubated in blocking/permeabilization buffer (BPB) 
(10% normal goat serum(Vector Laboratories) and 0.2% Triton X-100 in PBS) for 30 min, at RT. Anti-Lgy 
LRV1 capsid antibody (45) was added (1:20,000 dilution) and incubated at RT for 1 hr. After two washes 
with PBS, cells were resuspended in 200 μl BPB with Alexa488-labeled goat-anti-rabbit antibody 
(Thermo Fisher) (1:2,000 dilution) and incubated 1 hr at RT. After two additional washes with PBS, cells 
were subjected to flow cytometry and the data analyzed using CellQuest© software (BD Bioscience). 
Western blot, macrophage infections and cytokine assays. 
After an initial wash with PBS, 5x107 parasites were resuspended in 100 µL of 1x PBS. 1x107 cells (20 µL) 
were lysed with 7 µL of 4x Laemmli’s gel sample buffer. After heating for 5 min at 95 °C, cell lysates were 
loaded and separated on a 10% polyacrylamide denaturing gel, transferred to a nitrocellulose 
membrane and visualized by Ponceau Red staining. The membrane was blocked for 1h in 5% powdered 
milk diluted in TBS + 0.05% Tween20, incubated overnight at 4 °C with the g018d53 anti-capsid 
polyclonal antibody (1:5000 in 1% milk TBS-Tween20), washed 4x 15 min at RT, incubated for 1h with an 
anti-rabbit IgG antibody coupled to peroxidase (Promega) (1:2500 in 1% milk TBS-Tween20), washed 
again 4x and finally revealed by ECL chemiluminescence (Amersham). Infections of BL6 mouse BMDM 
and cytokine assays were performed as previously described (7, 10). 
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Figure Legends 
Figure 1: Properties of Lbr siRNAs and sRNAs from Lbr and Lgy.  
A) Distributions of read lengths of siRNAs or sRNAs mapping to Leishmania genomes or LRV1s. Shown 
are 1) AGO1-bound siRNAs (black, solid) or sRNAs (black, dashed) from WT Lbr M2903 mapping to the 
Lbr genome, 2) Lgy M4147 sRNAs mapped to the Lg genome (blue, solid) or LRV1-LgyM4147 (blue, 
dashed), and 3) Lbr LEM2780 sRNAs mapped to the Lbr genome (green, solid) or LRV1-LbrLEM2780 
(green, dashed). B) Percentage of 23 nt sRNA reads (20-26nt) mapping to transposable elements (TEs, 
white), rRNA (red), tRNAs (black), genomic repeat regions (yellow), LRV1 (purple), and other Leishmania 
genomic regions (other, gray).  
Figure 2: RNAi constructs for LRV1 elimination. 
A) Schematic of an RNAi “stem-loop” (StL) construct. Each construct includes an inverted repeated 
sequence containing 800-1200 bp of the target gene (gene of interest, GOI) and a hygromycin drug 
resistance marker (HYGR). The construct is flanked with sequence of the small subunit ribosomal RNA 
gene, which allows it to integrate into this locus, where it is transcribed at high levels. Splice acceptor 
(SA) signals within the construct allow for polyadenylylation and processing.  
B) Schematic showing LRV1 genome organization and regions targeted for RNAi StL constructions (thick 
bars) from Lbr LEM2700, LEM2780, and LEM3874, and Lgy M4147 targeted by RNAi (white, capsid; gray, 
RDRP). The locations of qPCR amplicons for quantification of LRV1 levels are shown (thin black bars).  
Figure 3: Loss of LRV1 induced by RNAi  
Anti-capsid flow cytometry analysis of LRV1-knockdown lines in Lgy M4147 and Lbr LEM2780 (top and 
bottom panels respectively). LRV1 capsid protein levels are unchanged in GFP65 StL lines, while LRV1 StL 
lines have undetectable capsid protein. Red, parent lines; purple, GFP65 StLs (off target control); green, 
LRV1-negative controls; light blue, Capsid StL; dark blue, RDRP StL. 
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Figure 4. Overexpression of LRV1-mapping 23 nt sRNAs in LRV1 StL transfectants. 
A) Genomic mapping of 23 nt sRNA reads from sRNA sequencing of parental or capsid StL Lgy M4147
(left) or capsid-RDRP StL Lbr LEM3874 (right) mapping to transposable elements (TEs, white), rRNA (red), 
tRNAs (black), genomic repeat regions (yellow), LRV1 (purple), and other Leishmania genomic regions 
(other, gray). B) LRV1 mapping of 23 nt sRNA reads from LRV1StL lines described in panel A (Lgy M4147, 
top; Lbr LEM3874, bottom). Light gray trace indicates parental read distributions; dark gray trace 
indicates LRV1 StL read distributions. The dark box indicates the region targeted by the StL stems. 
Figure 5: The LRV1 genome is completely lost in most LRV1-StL transfectants 
qPCR analysis of LRV1 RNA levels in LRV1 StL transfectant clones of Lbr LEM2700 (A) and Lgy M4147 (B), 
along with positive and negative controls (+ and – respectively) and control GFP65 StL transfectants. 
White bars denote a non-specific qPCR product, while black bars denote an LRV1-specific amplicons 
(melt curve analysis). Dashed line indicates cutoff for designating a clone as LRV1-negative. Error bars 
are the standard deviation of three technical replicates for each line. 
Figure 6. LRV1 elimination results in decreased release of cytokines from infected macrophages. 
TNF-α or IL-6 levels were quantified 24h after infection of macrophages with Lbr LEM2780 (A) or Lg 
M4147 (B) parent, GFP65 knockdown control, or LRV1-StL transfectants. In both studies the LRV1- 
control was Lgy M4147. For A, results are averages of two-three technical replicates for two clones of 
each line. For B, results are the averages of two technical replicates for three to six clones of each line. 
NS, not significant; ** p < 0.01; *** p < 0.0001 by t-test. 
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Supplementary Information 
Supplemental Table Legends 
Table S1:  23 nt siRNA analysis to Leishmania genome and LRV1. For Lbr, Lbr M2904 reference genome 
was used, and for Lgy, a M4147 draft genome (BioProject PRJEB168, accession numbers 
HG800646-HG802771) was used. References for viral genomes are sequences reported in this 
work. 
Table S2:  Distributions of reads mapped to Lbr and Lgy genomes for Ago1-bound siRNAs, 23 nt (20-26 
nt) and 33 nt (30-36 nt ) sRNAs. 
Table S3:  Primer sequences used to amplify regions of LRV1 for cloning into stem-loop constructs. 
Table S4:  Primer sequences used to measure LRV1 RNA levels by qPCR. 
Supplemental Figure Legends 
Supplemental Figure 1: Properties of Lbr siRNAs and 23 nt sRNAs from Lbr and Lgy. 
This figure shows mapping of the indicated small RNAs after ‘collapsing’ the data to remove duplicate 
reads. Shown are the percentages of 23 nt sRNA reads (20-26nt) mapping to transposable elements 
(TEs, white), rRNA (red), tRNAs (black), genomic repeat regions (yellow), LRV1 (purple), and other 
Leishmania genomic regions (other, gray). A) As in Figure 1B, mappings in WT parent lines. B) As in 
Figure 4A, comparing parental lines with capsid StL Lgy M4147 (left) or capsid-RDRP StL Lbr LEM3874 
(right). 
Supplemental Figure S2: Mapping of 23nt sRNA reads (20-26 nt) from the respective parasite lines to 
LRV1-LbrLEM2700 (A), LRV1-LbrLEM2780(b) (B), LRV1-LbrLEM3874 (C), and LRV1-LgyM4147 (D). Reads 
mapping to the positive strand, (light gray); negative strand, (dark gray). 
Supplemental Figure S3: Capsid protein is lost in Lgy M4147 capsid StL transfectants.  
Three GFP65 StL control clones and six Capsid StL clones were evaluated. Top panel: Western blot 
analysis was performed using g018d53 anti-capsid polyclonal antibody (35). The arrow marks the 
location of the capsid protein band. Bottom panel: Ponceau S stain of protein gel.   
Supplemental Figure S4:  qPCR analysis of LRV1 RNA levels in LRV1 StL clones of L. braziliensis strain 
LEM2780 (A), L. braziliensis strain LEM3874 (B), and re-cloned L. guyanensis M4147 RDRP StL c3 (C). 
White bars denote a non-specific product; black bars denote an LRV1-specific product (melt curve 
analysis). Dashed line indicates cutoff for designating a clone as LRV1-negative. Error bars are the 
standard deviation of three technical replicates for each line. 
Supplemental Figure S5: Infection of macrophages by Lbr LEM2700 (A) and Lgy M4147 (B).  
TNF-α or IL-6 levels were quantified 24h after infection of macrophages with Lbr (A) or Lgy (B) parasites. 
NI, not infected; LRV1+ or LRV1-, infected with Lgy M4147 LRV1+ or LRV1-negative cells; GFP65 StL 
transfectants; and RDRP StL or capsid StL transfectants. A) Results are the averages of two technical 
replicates of two clones per line. Dark gray bars, experiment performed using WT macrophages; light 
gray bars, experiment performed using TLR3 knockout macrophages. B) Results are the averages of two 
technical replicates for each representative clone indicated. Lines found to be LRV1+ by qPCR are 
denoted by black bars; white bars are lines found to be LRV1-negative by qPCR. 
 Table S1: Summary of sRNA reads and mapping 
A.  Total Reads. 
Sample Total reads (raw) 
Total Trimmed Reads aligned to the Leish. genomes + viruses (Percent total) 
Aligned  33 nt peak reads to Leishmania (% alignable reads) 
Aligned 23 nt peak reads to Leishmania (% alignable reads) 
Aligned 23 nt peak reads to LRV1 (% alignable reads) 
Percent with 3’ extension (Leishmania) 
Percent with 3’ extension (LRV1) 
Genome-mapping reads 3' extension base A-T-C-G (%) 
Lbr M2903a 29,391,347 19,447,509  (66.2%) 1,827,623 (9.40 %) 15,147,603 (77.9 %) n/a 21 n/a 43-41-8-8 Lbr LEM2700 40,384,483 29,473,443  (73.0%) 8,055,506 (27.3%) 15,540,670 (52.7%) 59,287 (0.20%) 19 20 43-41-7.9-8.1 Lbr LEM2780b 48,615,815 34,959,518 (71.9%) 5,121,894 (14.7%) 25,361,713 (72.5%) 326,021 (0.93%) 20 20 43-40-7.8-8.2 Lbr LEM3874 36,543,649 25,591,362 (70.0%) 4,052,707 (15.8%) 16,756,188 (65.5%) 347,022 (1.36%) 19 19 44-41-6.6-7.4 
Lgy M4147 55,220,664  37,159,548  (67.3%) 1,261,927 (3.40 %) 25,489,186 (68.6 %) 660,143 (1.78%) 15 13 32-33-19-15 
B. Collapsed Reads 
Sample Total reads (raw) 
Total Trimmed Reads aligned to the Leish. genomes + viruses 
Aligned  33 nt peak reads to Leishmania (% alignable reads) 
Aligned 23 nt peak reads to Leishmania (% alignable reads) 
Aligned 23 nt peak reads to LRV1 (% 23 nt reads) 
Percent with 3’ extension (Leishmania) 
Percent with 3’ extension (LRV1) 
Genome-mapping reads 3' extension base A-T-C-G (%) 
Lbr M2903a 2,327,188 1,038,131 (44.6%) 68,895 (6.64%) 776,204 (74.8 %) n/a 37 n/a 35-35-15-15 
Lbr LEM2700 2,948,017 1,206,587 (40.9%) 127,998 (10.6%) 758,664 (62.9 %) 18,642 (1.54%) 35 36 34-34-16-16 
Lbr LEM2780b 3,439,169 
1,777,142 (51.7%) 150,229 (8.45%) 1,050,094 (59.1 %) 61,753 (3.47%) 33 34 34-34-16-16 
Lbr LEM3874 2,379,761 
1,224,741 (51.5%) 105,696 (8.63%) 632,961 (51.7%) 48,287 (3.94%) 31 32 35-35-15-15 
Lgy M4147 1,437,673 752,464 (52.3%) 152,059 (20.2%) 358,039 (47.6%) 43,099 (5.73%) 22 22 30-28-22-20 
a Lbr M2903 SSU:IR2-LUCSR.   b The sum of reads mapping to LRV1-LbrLEM2780(a) and (b) are shown, which map quantitatively to similar levels. 
  
Table S2. Genomic mapping of 23 and 33 nt ‘peak’ sRNA fractions from Lbr and Lgy. 
      
 Lbr M2903 Lgy M4147 
 AGO1-bound siRNAs 
23 nt  (20-26 nt) sRNAs 
33 nt  (30-36 nt)  sRNAs 
23 nt  (20-26 nt)  sRNAs 
33 nt  (30-36 nt)  sRNAs  Alignable reads  20,029,304  19,447,509  1,827,623  37,159,548  1,261,927 
 Percent mapping to:       Transposable elements 
     
SLACS   33.9 26.9 1.2 59.8 0.25 TATE   45.1 53.1 5.2 10.7 0.32  Repeats      Misc.   5.8 5.0 7.7 1.1 2.4 TAR   4.7 4.2 0.08 4.0 0.38 TAS   4.2 5.1 20.3 4.8 6.5 CIR   5.1 4.6 0.09 0.0 0.0  Structural RNAs      tRNAs   0.12 0.75 32.1 9.9 75.4 rRNAs    0.42 0.47 29.4 5.5 14.6        
Transposable elements, repeats and structural RNAs were classified as defined in the Methods and by Atayede et al (26) 
 
 Table S3: Primer sequences used to amplify regions of LRV1 for cloning into stem-loop (StL) constructs. 
Parasite strain Target Construct ID Name Stem length Sequence - is the border or the oligo? Some look like one some the other 
Lbr LEM2700 
Capsid B6910  pIR2HYG-LRV1_LbrLEM2700_CapsidStL(A) 943 bp 
5’-CGCTAGTCTAGAATACTACAGCAAACATGTTTCG 
  5’-CGCTAGTCTAGACAAGGTGTCTGTTGGGTTCGAT 
RDRP 
B6908  pIR2HYG-LRV1_LbrLEM2700_RDRPStL(A) 1143 bp 
5’-CGCTAGTCTAGAATGTGCTTCAAACTTGAAGATG 
  5’-CGCTAGTCTAGATAGCAGCAATCTAACGACCTGC 
Lbr LEM2780 
Capsid 
B7061  pIR2HYG-LRV1_LbrLEM2780_CapsidStL(A) 835 bp 
5’-CCAGCTTGGGATCAATTTGCGG 
  5’-GGACATCTCCATCAGCCGATGA 
RDRP 
B7062  pIR2HYG-LRV1_LbrLEM2780_RDRPStL(A) 794 bp 
5’-GTGAGGATGAGTTGCGCGCTGC 
  5’-ATTGCTAAGTAGACTGTTTGCG 
Lbr LEM3874 Capsid / RDRP 
B7268  pIR2HYG-LRV1_LbrLEM3874_StL(A) 1000 bp 
5’-GGCTAGTCTAGA GTCGTGCGATCTATTCCATCCT 
  5’-GGCTAGTCTAGATTAGTGCTTATGTTAGGATCAG 
Lgy M4147 
Capsid 
B7066  pIR2HYG-LRV1_LgyM4147_CapsidStL(A) 926 bp 
5’-CTTCTCCTTTACGTGCCAGC 
  5’-GCGCATTGTTGTCCACTCAA 
RDRP 
B7063  pIR2HYG-LRV1_LgyM4147_RDRPStL(A) 829 bp 
5’-CTTGCTAGGTCGTGGGGTGA 
  5’-ACCAACATGCATAGACGTGG 
 
  
Table S4: Primer sequences used in measurement of LRV1 RNA levels by qRT-PCR. 
 
 
 
 
 
KMP-11 F 5’-GCCTGGATGAGGAGTTCAACA R 5’-GTGCTCCTTCATCTCGGG L. braziliensis LEM2700 F 5’-CATCCTGCTGAGTTGACTTCATAC R 5’-GTCACACCTTGTGATGACATTGC L. braziliensis LEM2780 F 5’-GTCATTACGAGGTGTGATGGAAT R 5’-GGTAACGCGCCATCACACAGT L. braziliensis LEM3874 F 5’-GAATATGCTCTCCGACCGGTTG R 5’-AATTCTCGCAGCCACCCCACAG L. guyanensis M4147 Set 1 F 5’-CTGACTGGACGGGGGGTAAT Set 1 R 5’-CAAAACACTCCCTTACGC Set 2 F 5’-CACGCTAGATGAGTACATCTGG Set 2 R 5’-GTAGTTGCGGAATCTGACG Set 3 F 5’-GGTAATATCACGCAGTGTAAGC Set 3 R 5’-GACACCACCTCTAAGACACG 
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